Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FlexHD vs Alloderm in Breast Reconstruction
NCT02372305Phase 4Withdrawn
- Sponsor
- University of Arkansas
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by University of Arkansas. Primary endpoint: Wound Dehiscence at 1 year. Planned start Mar 2016; status: withdrawn.
Beyond the preview
Go deeper on NCT02372305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02372305.